Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

• About the I-neb AAD
  System

•      How the AAD System
       Works

•      Cleaning the AAD System

•      Breathing Technique

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Components

I-Neb AAD System Components

• One I-Neb
• Two Ventavis Dosing Discs
  • Two 2.5mcg discs (red)
  • Two 5.0mcg discs (purple)
• Two Medication Chamber Assemblies
  • 2.5mcg -One Mouthpiece, One Chamber Lid/Mesh and One Drug Guide
  • 5.0mcg -One Mouthpiece, One Chamber Lid/Mesh and One Drug Guide
• One Washing Basket
• One Battery Assembly (Charger and Powercord)
• One I-Neb Carrying Case
• Instructional Materials-Quick Start Guide and User Guide (English and Spanish)

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information